Trial · NCT01352845
Results by group595
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 595
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1 | Group 1 rLP2086 | Composite hSBA response (N=1664) | 84.9 | 95% Confidence Interval 83.1 to 86.6 | Percentage of participants |
Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1 | Group 1 rLP2086 | PMB80 [A22] (N=1695) | 80.5 | 95% Confidence Interval 78.6 to 82.4 | Percentage of participants |
Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1 | Group 1 rLP2086 | PMB2001 [A56] (N=1642) | 90.0 | 95% Confidence Interval 88.4 to 91.4 | Percentage of participants |
Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1 | Group 1 rLP2086 | PMB2948 [B24] (N=1675) | 79.3 | 95% Confidence Interval 77.3 to 81.2 | Percentage of participants |
Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1 | Group 1 rLP2086 | PMB2707 [B44] (N=1696) | 79.6 | 95% Confidence Interval 77.6 to 81.5 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Pain at injection site: Any | 84.2 | 95% Confidence Interval 82.7 to 85.6 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Pain at injection site: Any | 11.8 | 95% Confidence Interval 9.6 to 14.2 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Pain at injection site: Mild | 42.3 | 95% Confidence Interval 40.3 to 44.3 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Pain at injection site: Mild | 10.7 | 95% Confidence Interval 8.6 to 13.0 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Pain at injection site: Moderate | 37.1 | 95% Confidence Interval 35.1 to 39.0 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Pain at injection site: Moderate | 1.1 | 95% Confidence Interval 0.5 to 2.1 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Pain at injection site: Severe | 4.8 | 95% Confidence Interval 4.0 to 5.8 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Pain at injection site: Severe | 0.0 | 95% Confidence Interval 0.0 to 0.5 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Redness: Any | 13.8 | 95% Confidence Interval 12.5 to 15.3 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Redness: Any | 0.6 | 95% Confidence Interval 0.2 to 1.5 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Redness: Mild | 5.8 | 95% Confidence Interval 4.9 to 6.8 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Redness: Mild | 0.5 | 95% Confidence Interval 0.1 to 1.3 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Redness: Moderate | 7.1 | 95% Confidence Interval 6.1 to 8.2 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 2 Saline | Redness: Moderate | 0.0 | 95% Confidence Interval 0.0 to 0.5 | Percentage of participants |
| Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination | Group 1 rLP2086 | Redness: Severe | 0.9 | 95% Confidence Interval 0.6 to 1.4 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01352845/results